DAEWOONG PHARMACEUTICAL CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,09,700 KRW | -0.90% |
|
-1.97% | -6.08% |
| 24/04 | Korean Sugar Imports Plunge 14% as Diabetes Cases Surge | MT |
| 12/04 | AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd | CI |
ETFs positioned on Daewoong Pharmaceutical Co., Ltd
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 112 M€ | +4.06% | - |
Daewoong Pharma is a Korea-based company principally engaged in the manufacture and distribution of pharmaceuticals. The Company's products mainly include antihypertensive drugs, antianemic agents, antidiabetic agents, antiemetic agents, antihistamine agents, antimicrobials, antineoplastics, antiobesity agents, antipyretic agents, analgesic agents, anti-inflammatory agents, biosimilars, remedies for bone and joint diseases, cardiovascular treatments, central nervous system treatments, digestive agents, dermatologic agents, gastrointestinal agents, health supplements and respiratory remedies, among others. The Company distributes its products in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
13/11/2024
- Q3 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -6.08% | 93Cr | |
| +21.09% | 4.33TCr | |
| +25.39% | 2.29TCr | |
| +19.22% | 1.54TCr | |
| +13.51% | 1.29TCr | |
| +44.01% | 1.18TCr | |
| -6.70% | 691.1Cr | |
| -0.05% | 678.76Cr | |
| -8.87% | 572.55Cr | |
| +13.26% | 554.99Cr |
- Stock Market
- Equities
- A069620 Stock
- Funds and ETFs Daewoong Pharmaceutical Co., Ltd